Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.850
+0.270 (10.47%)
At close: Nov 6, 2026, 4:00 PM EST
2.860
+0.010 (0.35%)
After-hours: Nov 6, 2026, 7:30 PM EST
Ovid Therapeutics Revenue
Ovid Therapeutics had revenue of $733.00K in the quarter ending June 30, 2026, a decrease of -88.31%. This brings the company's total for the last twelve months to $1.58M, down -76.20% year-over-year. In the year 2025, Ovid Therapeutics had annual revenue of $7.25M with 1,181.27% growth. That makes Ovid Therapeutics the 42,839th largest company in the world by revenue and 5,890th in the United States.
Revenue (ttm)
$1.58M
Revenue Growth
-76.20%
P/S Ratio
351.61
Revenue / Employee
$68,826
Employees
23
Market Cap
556.60M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.25M | 6.69M | 1,181.27% |
| Dec 31, 2024 | 566.00K | 174.00K | 44.39% |
| Dec 31, 2023 | 392.00K | -1.11M | -73.91% |
| Dec 31, 2022 | 1.50M | -206.88M | -99.28% |
| Dec 31, 2021 | 208.38M | 195.77M | 1,551.57% |
| Dec 31, 2020 | 12.62M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 163.30M |
| Surrozen | 11.51M |
| Capricor Therapeutics | 11.13M |
| SL Science Holding | 3.27M |
| Neurogene | 925.00K |
| Entera Bio | 42.00K |
OVID News
- 1 day ago - Ovid Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 22 days ago - Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer - PRNewsWire
- 22 days ago - Ovid Therapeutics initiated with an Outperform at Wolfe Research - TheFly
- 4 weeks ago - Ovid Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 4 weeks ago - Ovid Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 4 weeks ago - Ovid Therapeutics management to meet with B. Riley - TheFly
- 4 weeks ago - Guggenheim starts Ovid Therapeutics with a Buy on OV329 potential - TheFly
- 4 weeks ago - Ovid Therapeutics initiated with a Buy at Guggenheim - TheFly